CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Cellectis S.A.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026

$0.93−0.11 (-11.01%)

Close on Oct 19, 2026

Market cap: $93.15M
P/E (TTM): –
Dividend yield: –

Cellectis S.A. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Revenue	73	42	0.76	19	30	51	15	13	25	45	56	–
Cost of Revenue	0	0	0.74	1.77	1.84	1.95	11	2.74	2.62	–	–	–
Gross Profit	73	42	0.02	17	29	49	3.80	9.99	23	–	–	–
Research & Development	94	91	88	98	118	77	92	77	79	78	58	–
Selling, General & Admin	20	19	17	17	23	23	43	47	45	43	30	–
Operating Expenses	–	109	106	115	142	102	147	127	126	124	94	42
Operating Income	-33	-60	-97	-90	-103	-42	-124	-105	-93	-67	-31	-6.97
Interest Expense	51	22	41	18	6.49	16	3.63	3.81	18	7.10	1.88	–
Interest & Investment Income	16	44	21	8.88	13	4.85	12	21	7.26	7.15	10	–
Pretax Income	-68	-37	-116	-99	-97	-54	-115	-88	-104	-67	-23	–
Income Tax Expense	-0.42	0	0.37	0.09	0	0	0	0	0	0	0	0
Income from Continuing Operations	-68	-37	-117	-99	-97	-54	-115	-88	-104	-67	-23	2.46
Income from Discontinued Operations	0	0	8.39	-15	-28	-44	-115	-88	0	0	0	-3.75
Net Income incl. Noncontrolling Interests	-68	-37	-108	-114	-125	-97	-115	-88	-104	-67	-23	-1.29
Minority Interest in Earnings	0	0	-7.38	-7.89	-11	-16	-13	-9.64	-4.32	–	0.19	–
Net Income	-68	-37	-101	-106	-114	-81	-102	-79	-99	-67	-23	–
Net Income to Common	–	–	-101	-106	-114	-81	-102	-79	-99	-0.07	-0.02	–
EPS (Basic)(per share)	-0.67	-0.41	-1.77	-2.33	-2.55	-1.91	-2.41	-1.93	-2.78	-1.91	-0.67	–
EPS (Diluted)(per share)	-0.67	-0.41	-1.77	-2.33	-2.55	-1.91	-2.41	-1.93	-2.78	-1.91	-0.67	–
Shares Outstanding (Basic, Weighted)(shares)	100	91	57	46	45	43	42	41	36	35	34	–
Shares Outstanding (Diluted, Weighted)(shares)	100	91	57	46	45	43	42	41	36	35	34	–
EBITDA	-13	-40	-79	-71	-89	-34	-117	-103	-89	-65	-29	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 100.0%
Operating margin: -45.3%
Net margin: -92.7%
Return on equity, FY2025: -65.3%

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 26.4%

Valuation

P/E ratio: –
Price to sales: 1.28
Price to book: 2.27
Dividend yield: –